CytoMed Therapeutics (GDTC) Receivables - Other (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Receivables - Other for 5 consecutive years, with $375976.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Other changed 0.02% to $375976.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $375976.0 through Dec 2025, changed 0.02% year-over-year, with the annual reading at $372965.0 for FY2025, 0.36% changed from the prior year.
  • Receivables - Other hit $375976.0 in Q4 2025 for CytoMed Therapeutics, roughly flat from $375888.2 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $375976.0 in Q4 2025 to a low of $15122.4 in Q4 2021.
  • Historically, Receivables - Other has averaged $197279.6 across 5 years, with a median of $191928.2 in 2023.
  • Biggest five-year swings in Receivables - Other: soared 598.35% in 2023 and later grew 0.02% in 2025.
  • Year by year, Receivables - Other stood at $15122.4 in 2021, then skyrocketed by 81.74% to $27483.0 in 2022, then skyrocketed by 598.35% to $191928.2 in 2023, then surged by 95.85% to $375888.2 in 2024, then rose by 0.02% to $375976.0 in 2025.
  • Business Quant data shows Receivables - Other for GDTC at $375976.0 in Q4 2025, $375888.2 in Q4 2024, and $191928.2 in Q4 2023.